MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.18
-1.75
-3.81%
After Hours: 44.18 0 0.00% 16:44 07/13 EDT
OPEN
46.38
PREV CLOSE
45.93
HIGH
47.21
LOW
44.13
VOLUME
656.68K
TURNOVER
--
52 WEEK HIGH
55.12
52 WEEK LOW
15.19
MARKET CAP
5.61B
P/E (TTM)
-66.5361
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADPT stock price target is 52.25 with a high estimate of 60.00 and a low estimate of 45.00.

EPS

ADPT News

More
Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020
Motley Fool · 4d ago
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020
GlobeNewswire · 4d ago
2 Stocks That Could Make You Rich
MotleyFool.com · 06/25 11:08
Hedge Funds Never Been Less Bullish On Adaptive Biotechnologies Corporation (ADPT)
Insider Monkey · 06/23 16:54
Is Amgen Stock a Buy?
MotleyFool.com · 06/18 13:31
How Adaptive Biotechnologies (ADPT) Stock Stands Out in a Strong Industry
Zacks · 06/17 13:56
Microsoft (MSFT) and Adaptive Roll Out ImmuneCODE Database
Zacks · 06/15 15:27
ArcherDx Begins U.S. IPO Rollout
Seeking Alpha - Article · 06/11 19:03

Industry

Biotechnology & Medical Research
-1.52%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Symbol
Price
%Change

About ADPT

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
More

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.